Compugen Ltd Q2 Loss Drops

Compugen Ltd (CGEN) reported a Q2 GAAP net loss of $7.01 million, or $0.07 per share, improving from a $7.34 million loss, or $0.08 per share, a year earlier. Revenue rose 106.3% to $2.60 million from $1.26 million, according to the company.

Original reporting
Published Aug 3, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CGEN
Bearish
medium confidence
Mentioned
$CGEN
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CGENBearishLow
01

Why it matters

Investors will likely weigh the large year-over-year revenue increase against the still-material GAAP net loss of $7.01M.

02

Market read

This is a straightforward earnings datapoint with revenue growth but continued losses, offering limited incremental decision-making without guidance or cash-flow context.

03

What to watch

No cash balance, operating expense trend, guidance, or backlog is provided, so the market may need additional filings to judge whether losses are controllable.

Relevance 5/10Novelty 5/10Timing: Q2 results reported today (2026-08-03)

Background

The article summarizes Compugen’s Q2 GAAP results, comparing them to the prior year.

Company-level read

Ticker impact

$CGENBearishMedium confidence
Context

Compugen reported Q2 GAAP net loss of $7.01M, with revenue up 106.3% to $2.60M, versus prior-year $1.26M.

Expected impact

Likely downside or choppy trading if investors focus on losses outweighing revenue growth.

Evidence & confidence

The article provides only GAAP loss and revenue growth, with no guidance or balance-sheet/cash detail to offset the loss trend.

Market effects

Limited read-through because the article lacks segment, customer, or product details beyond revenue and GAAP loss.

None indicated.

None indicated.

Counterpoint

Revenue more than doubled year over year, which could indicate improving traction that may eventually reduce losses if costs scale slower.

Key entities

  • Compugen Ltd

    Reported Q2 GAAP net loss of $7.01M and revenue of $2.60M, up 106.3% year over year.

Related articles

$CGENMed

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

$CGENMed

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.